Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

Pharmacyclics to maintain all US Rights Conference Call to discuss the company's third quarter financial results is scheduled for April 23, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT). SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced...

PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy

... Muscular Dystrophy Association ( www.mdausa.org ), Parent Project Muscular Dystrophy ( www.parentprojectmd.org ) and the Association Francaise contre les Myopathies ( www.afm-france.org ). About Ataluren (PTC124(TM)) Ataluren is an orally delivered, investigational new drug discovered by PTC Th...

Isogen Launches Major New Facility to Address Global Biopharma Demand

... will help our customers address major industry dynamics that are reshaping the face and complexity of sterile clinical trials materials supply," said les Edwards, CEO, Isogen. "Regulators in the U.S. and Europe increasingly require sterile clinical trials supplies to be manufactured in accordance with c...

Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed

..., does not close properly. This valve opens to allow food and liquids to enter the stomach and closes to keep acid and food in the stomach. When the les does not close as tightly as it should, or relaxes too often, it can allow stomach contents to enter the esophagus repeatedly. The stomach is better e...

Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children

...jected clinical protocol, this work - published in the review Nature Medicine - has received the financial backing of the Association Francaise contre les Myopathies (Muscular Dystrophy Association) thanks to French Telethon donations. The treatment recently validated in mice is based on a combination ...

Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers

...ease toxicity," Pui said. "That way, we don't over treat low-risk patients or under treat high-risk patients." Other authors of this paper include les Robison (St. Jude) and A. Thomas Look (Dana-Farber Cancer Institute and Harvard Medical School, Boston). This work was supported in part by grants...

Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)

...gress. This is our second Phase 2 study of PS433540 in hypertensive patients to provide key indications of the compound's therapeutic potential," said les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We look forward to the completion of this study by the end of 2008 as well as t...

Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)

...development timeline, but we have now completed enrollment in the study with the expectation of reporting results in the second quarter of 2008," said les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "As this is the first PS433540 study to include hypertensive patients, we are ple...

Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development

...engthens Pharmacopeia's internal pipeline with a wholly-owned development candidate with the potential to address significant therapeutic needs," said les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We believe this nomination is a testament to our drug discovery expertise which...

AHF Seeks White House Clarification After Press Room Flap Over CDC's HIV Numbers

...ation from the White House regarding a press briefing late last week during which Deputy Press Secretary Dana Perino had a curt exchange with reporter les Kingsolving over questions he tried to pose regarding the Centers for Disease Control (CDC) and its latest US HIV data. Kingsolving, from the ultra-co...

Pharmacopeia Announces Third Quarter 2007 Financial Results

...recent clinical progress with PS433540 as well as the in-licensing of our new SARM program has significantly enhanced Pharmacopeia's pipeline," stated les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "We now have two of our own programs in clinical development as well as two partn...

Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate

...ring-Plough as a result of this trial initiation. "The Schering-Plough collaboration continues to yield very attractive therapeutic candidates," said les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "This compound is the third drug candidate resulting from the collaboration that...

Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration

...ase inhibitors could be effective in a range of inflammatory diseases including psoriasis, rheumatoid arthritis, and inflammatory bowel disease," said les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "Psoriasis is an important indication to evaluate in order to rapidly achieve pr...

Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)

...iated this important Phase 2a concept validation study of PS433540 approximately six months ahead of our original clinical development timeline," said les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "The goal of this study is to prove that PS433540 lowers blood pressure in hyper...